9月5日，欧林生物大宗交易成交27.9万股，成交额701.96万元，占当日总成交额的2.73%，成交价25.16 元，较市场收盘价28元折价10.14%。 | 交易日期 | 任务简称 | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 英入营业部 | | 美出精变部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | | 2025-09-05 | 欧林生物 | 61E889 25.16 | 400.04 15.9 | 国投证券股份有限 公司河源分公司 | 广发证券股份有限 公司成都善山大道 | 199 | | | | | | | 短發電來設 | | | 2025-09-05 | 欧林生物 | 688319 25.16 | 301.92 12 | 中信证券股份有限 | 广发证券股份有限 | 종 | | | | | | 公司总部(非常业 | 公司成松峰山大道 | | | | | | | 场所 | 证券管业部 | | ...

Core Points - Olin Bio announced that as of the disclosure date, the financial officer and vice president, Mr. Tan Yong, holds 571,440 shares, accounting for 0.14% of the total share capital [1] - The company’s secretary of the board and vice president, Mr. Wu Wei, holds 778,400 shares, representing 0.19% of the total share capital [1] - Both executives plan to reduce their holdings through centralized bidding, with Mr. Tan Yong intending to sell up to 128,860 shares and Mr. Wu Wei up to 178,500 shares within three months after the announcement, starting 15 trading days from the disclosure [1]

Core Viewpoint - The announcement details the share reduction plans of senior management personnel at Chengdu Olin Biological Technology Co., Ltd., specifically financial officer Tan Yong and secretary of the board Wu Wei, who plan to reduce their holdings for personal financial planning reasons [3][12]. Summary by Sections Senior Management Shareholding Overview - As of the announcement date, financial officer Tan Yong holds 571,440 shares, representing 0.14% of the total share capital, with 515,440 shares being tradable and 56,000 shares being restricted [2]. - Secretary of the board Wu Wei holds 778,400 shares, accounting for 0.19% of the total share capital, with 714,000 shares being tradable and 64,400 shares being restricted [2]. Details of the Reduction Plan - Tan Yong and Wu Wei plan to reduce their holdings by up to 128,860 shares and 178,500 shares, respectively, through centralized bidding within three months after the announcement [3][12]. - The number of shares to be reduced will be adjusted if any corporate actions such as dividends or stock splits occur during the reduction period [3]. - Both individuals are compliant with regulations regarding share reductions and do not fall under any prohibitive conditions [3][12]. Background of the Reducing Parties - The reducing parties do not have any concerted actions with other shareholders [4]. - Neither Tan Yong nor Wu Wei has reduced their holdings since the company went public [5]. Commitments and Regulations - Tan Yong and Wu Wei have made commitments regarding their shareholding, including not transferring shares within 12 months of the company's listing and adhering to specific conditions if the company has not achieved profitability [7][8]. - They are also bound by regulations that limit the amount of shares they can sell within certain time frames and under specific conditions [8][9].

Core Viewpoint - Senior management personnel of Chengdu Olin Biological Technology Co., Ltd. plan to reduce their shareholdings due to personal financial needs, with specific limits on the number of shares to be sold and the timeframe for the reduction [1][2][3]. Summary by Relevant Sections 1. Basic Information of Senior Management Shareholdings - As of the announcement date, the financial officer and deputy general manager, Mr. Tan Yong, holds 571,440 shares, accounting for 0.14% of the company, with 277,440 shares obtained before the IPO and 238,000 shares through other means [2]. - The company secretary and deputy general manager, Mr. Wu Wei, holds 778,400 shares, accounting for 0.19% of the company, with 204,000 shares obtained before the IPO and 510,000 shares through other means [2]. 2. Details of the Reduction Plan - Mr. Tan plans to reduce his holdings by no more than 128,860 shares, representing up to 0.0317% of the total shares [2][3]. - Mr. Wu plans to reduce his holdings by no more than 178,500 shares, representing up to 0.0440% of the total shares [3]. - The reduction will occur through centralized bidding and block trading from September 26, 2025, to December 25, 2025 [3]. 3. Reasons for Reduction - The reduction is primarily due to personal financial needs of the senior management personnel [3]. 4. Compliance and Commitments - Both Mr. Tan and Mr. Wu have committed to not reducing their pre-IPO shares within a complete accounting year and have agreed to adhere to relevant regulations regarding share transfers [3][4].

Group 1 - The company, Olin Bio, announced that as of the disclosure date, its financial officer and deputy general manager, Mr. Tan Yong, holds approximately 570,000 shares, accounting for 0.14% of the total share capital [1] - Mr. Tan plans to reduce his holdings by up to approximately 128,900 shares, while the company’s board secretary and deputy general manager, Mr. Wu Wei, holds about 778,400 shares, representing 0.19% of the total share capital [1] - Mr. Wu also intends to reduce his holdings by up to approximately 178,500 shares within three months after the announcement of the reduction plan [1] Group 2 - For the year 2024, Olin Bio's revenue composition is primarily from the pharmaceutical manufacturing industry, which accounts for 99.53% of total revenue, with other businesses making up 0.47% [2] - The current market capitalization of Olin Bio is 11.1 billion yuan [3]

高级管理人员持有股份的基本情况 截至本公告披露日，公司财务负责人、副总经理谭勇先生持有公司股份 571,440 股，占公司总股本的比例为 0.14%。其中 515,440 股为无限售流通股， 来源为公司首次公开发行股票并上市前取得的股份以及非交易过户取得的股份， 56,000 股为限售流通股，来源为股权激励取得的股份。 证券代码：688319 证券简称：欧林生物 公告编号：2025-045 成都欧林生物科技股份有限公司 高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 截至本公告披露日，公司董事会秘书、副总经理吴畏先生持有公司股份 778,400 股，占公司总股本的比例为 0.19%。其中 714,000 股为无限售流通股， 来源为公司首次公开发行股票并上市前取得的股份以及非交易过户取得的股份， 64,400 股为限售流通股，来源为股权激励取得的股份。 减持计划的主要内容 公司于近日收到高级管理人员谭勇先生和吴畏先生出具的告知函，根据自身 财务规划，谭勇先生和吴畏先生 ...

格隆汇9月4日丨欧林生物(688319.SH)公布，公司于近日收到高级管理人员谭勇先生和吴畏先生出具的 告知函，根据自身财务规划，谭勇先生和吴畏先生计划通过集中竞价交易方式减持其持有的公司股份分 别不超过128,860股和178,500股，自本次减持股份计划公告披露之日起15个交易日后的3个月内实施。 ...

欧林生物(688319.SH)发布公告，公司于近日收到高级管理人员谭勇先生和吴畏先生出具的告知函，根 据自身财务规划，谭勇先生和吴畏先生计划通过集中竞价交易方式减持其持有的公司股份分别不超过 12.89万股和17.85万股，自本次减持股份计划公告披露之日起15个交易日后的3个月内实施。 ...

智通财经APP讯，欧林生物(688319.SH)发布公告，公司于近日收到高级管理人员谭勇先生和吴畏先生 出具的告知函，根据自身财务规划，谭勇先生和吴畏先生计划通过集中竞价交易方式减持其持有的公司 股份分别不超过12.89万股和17.85万股，自本次减持股份计划公告披露之日起15个交易日后的3个月内实 施。 ...

一、信息披露义务人及其一致行动人的基本信息 1.身份类别 ■ 2.信息披露义务人信息 ■ 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ■ 本次权益变动后，上海武山与一致行动人樊绍文、樊钒合计持有公司的股份数量由11,864.1245万股减少 至11,772.0745万股，占公司总股本的比例由29.22%减少至29.00%，权益变动触及1%刻度，具体情况如 下： ■ 三、其他说明 1、本次权益变动属于上海武山通过集中竞价交易方式履行此前披露的减持股份计划，公司实际控制人 樊绍文、樊钒以及公司董事陈爱民承诺通过上海武山间接持有的股份不参与本次减持。具体内容详见公 司于2025年7月23日在上海证券交易所网站（www.sse.com.cn）披露的《成都欧林生物科技股份有限公 司股东减持股份计划公告》（公告编号：2025-030）。 2、本次权益变动为公司控股股东的正常减持，不触及要约收购，亦不会导致公司的控股股东及实际控 制人发生变化，不会对公司治理 ...